News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

“We look forward to presenting updated data from our ongoing Phase 2 clinical study of palazestrant in combination with ribociclib in frontline metastatic breast cancer patients at SABCS in December.

A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...

University of Kentucky Markey Cancer Center researchers identified a protein that could be key to developing new treatments ...

This month, the NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines, for breast cancer were updated to recommend ribociclib as a ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

The women had early stage breast cancer that was HR-positive and HER2-negative. When compared to chemotherapy, the ribociclib and letrozole were found to be just as effective and better tolerated.

Common hormone therapies include: HER2-Positive Breast Cancer: Drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta) target the HER2 protein, which promotes cancer cell growth. CDK4/6 Inhibitors ...

A Michigan State University researcher's new model for studying breast cancer could help scientists better understand why and ...

Breast cancer rates rose by 1 percent per year from 2012-2021 for all U.S. women combined, with steeper increases for women under 50 and Asian American and Pacific Islander women, according to the ...

A team of scientists has used a novel approach to identify protein degraders that target Pin1, a protein involved in pancreatic cancer development. In drug discovery, targeted protein degradation is a ...